GRA_Logo

 + Home + About Us + Contact Us
+ Drug Delivery   + Monitoring & Diagnostics   + Healthcare    + Therapeutics    + Wound Care
 
Therapeutics


 Therapeutic Proteins to 2016
While the ability of recombinant protein drugs to treat previously refractory conditions continues to generate excitement and investment, the complex structure of these therapeutic substances require special formulation and delivery strategies, creating special challenges for drug developers and their formulation tech ........more

 Injectable Antibodies
The administration of therapeutic antibodies via injection is becoming an increasingly important healthcare treatment method for a growing number diseases and indications having broad implications for patient health and well-being. The inherent instability of protein drugs has led to a number of challenges as the developers .... more

 Patient Controlled Analgesia
An increasing understanding of the physiology of pain coupled with patient-friendly dosage forms and delivery techniques is providing caregivers and prescribers with improved tools for helping patient manage their own pain. New and emerging pain delivery products that allow patients to play an active role in the timing and dosing of their pain medication .... more

 Fentanyl: Products, Markets, Strategies and Opportunities
.....is available in sustained release dosage forms from a number of drug suppliers. Fentanyl has demonstrated effectiveness against breakthrough pain and has become a commonly prescribed pain medication for most forms of cancer. Controlled release formulations that include transdermal patches and transmucosal tablets .....more

 Controlled Release Cardiovascular Therapeutics
The prevalence and incidence of cardiovascular conditions in developed economies continue to increase, creating challenges and opportunities for cardiovascular drug developers. While the vast majority of drugs for treating cardiovascular conditions are oral immediate release products, issues related to .....more

 Autoimmune Disease Therapeutics to 2016
As a group, autoimmune diseases represent one of the most intractable families of conditions facing medical science. The complexities and genetic underpinnings of the human immune response result in a set of disease targets that are at once physiologically ubiquitous and highly individualized. Until recently, autoimmune disease patients were .....more

 Extended Release CNS Therapeutics
The availability of approved drugs for neurological disorders with extended release profiles creates the potential to improve patient compliance by extending the time between dosing intervals. Drugs that have been formulated as extended release versions include a number of well-known APIs that have traditionally been marketed as immediate release .....more

 Drug Coatings & Coated Device Drug Delivery
Advances in coating technology have given rise to a new generation of coating formulations that can reliably deliver therapeutic substances from the surface of an implanted medical device. In currently approved products, these devices provide a primary function, with the drug contributing therapeutic benefit that improves .... more

 Needle-free Injection
Much of the interest in needle-free injectors is focused on chronic diseases and refractory conditions – aliments that require frequent drug administration for a protracted period of .... more




 

 

Recent Research

Prefilled Syringes to 2016

Drug Self-Administration Markets to 2016

Therapeutic Proteins to 2016


Events

American Association for Clinical Chemistry (July 2012)

World Congress on Glucose Monitoring and Insulin Delivery (April 2012)

 
Greystone Research Associates
98 Route 101A, Suite 17
Amherst, NH 03031 USA

Phone: 603-595-4340/ Fax: 603-218-7020
Copyright 2011 ·  Greystone Research Associates  ·  All Rights Reserved · Conditions of Use  ·  Career